Sunday, February 28, 2021

AstraZeneca, Oxford Uni buoyed by ‘encouraging’ vaccine response

An AstraZeneca spokesman says the initial results 'further build the body of evidence for the safety and immunogenicity' of its experimental vaccine.

Other News

‘Jangan hipokrit, lidah bercabang’, kata Pemuda Amanah selepas PKR ‘curi’ 3 wakil rakyat

Sebagai rakan gabungan PH, menerima penyertaan wakil-wakil rakyat ini hanya akan mengeruhkan hubungan antara parti, kata Shazni.

Belajar sejarah di luar buku teks

Kalau dulu kita hanya ada maklumat dari buku teks, tetapi kini apa saja maklumat boleh diperolehi melalui alam maya.

’Sindir badan’ lebih dahsyat dengan media sosial

Media sosial kini menjadi medium paling mudah untuk seseorang meluahkan perasaan sehingga mengenepikan nilai kemanusiaan, kesopanan dan kesusilaan.

Contemptuous expressions and freedom of speech

Any business which maintains internet discussion forums should be aware of and guard against the risks of liability for comments by third parties.

Online shift makes body shaming easier than ever

A psychologist warns of the negative effects of such acts while a lawyer says legal action can be taken as it is considered a criminal offence.

British pharma giant AstraZeneca said on Monday trials of its coronavirus vaccine pioneered with Oxford University had shown “encouraging” responses among elderly, as well as younger participants.

The potential vaccine, one of 10 around the world in the most advanced phase III of trials, showed “strong immune responses” in all adult groups during the previous stage, according to an update from Oxford.

An AstraZeneca spokesman said the initial results “further build the body of evidence for the safety and immunogenicity” of its experimental vaccine.

“It is encouraging to see immunogenicity responses were similar between older and younger adults,” the spokesman added.

The positive news emerged in data on the safety and immune responses of participants in the phase II stage of the trial Oxford has submitted for peer review in a medical journal.

They include results for UK volunteers aged 56-69 and over 70, with formal publication of the data expected “in the coming weeks”.

“Our ongoing trials will provide further data, but this marks a key milestone and reassures us that the vaccine is safe for use and induces strong immune responses in both parts of the immune system in all adult groups,” the university said.

Oxford and AstraZeneca have been trialling their potential vaccine for months in various countries around the world.

It was suspended worldwide on Sept 6 after a participant’s illness, but resumed shortly thereafter in Britain, and in the following weeks in South Africa, Brazil and Japan.

Authorities determined the illness was not apparently linked to the vaccine, with the US Food and Drug Administration also authorising the restart in the US at the weekend.

The AstraZeneca/Oxford vaccine is one of the most promising and advanced in the world to combat the global pandemic, which has now claimed the lives of 1.1 million people.

Many countries are counting on using it to inoculate their populations.

The drugmaker pre-sold hundreds of millions of doses on several continents, and signed partnership deals with other producers to ensure the doses could be made locally.

UK Health Secretary Matt Hancock further fuelled optimism Monday, noting in an interview that once approved the “bulk” of the vaccine’s rollout could occur in Britain before next summer.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

New cases stay above 2,000 as 10 more deaths reported

190 in the ICU, 99 in need of respiratory assistance.

RM10,000 fine not for all SOP offences, top cop explains

Abdul Hamid Bador says the RM10,000 compound will not be issued for offences such as failure to wear face masks.

Too soon to say if Covid-19 jabs could allow immunity passports, says Noor Hisham

The health DG says other factors including the efficacy of the vaccines administered need to be taken into consideration first.

Khairy tells why he’s not taking Pfizer jab

The minister in charge of vaccine procurement is not among the key political leaders and individuals who have been administered the Pfizer vaccine.

Daily cases back over 2,000, death toll up by 11

2,253 new cases, 3,085 recoveries.